Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence

Journal of Clinical Psychopharmacology

Volumn 27, Issue 5, 2007, Pages 468-474

  Mannelli, Paolo ^a   Patkar, Ashwin A ^a   Peindl, Kathleen ^a   Murray, Heather W ^b   Wu, Li Tzy ^a   Hubbard, Robert ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE; NALTREXONE; OPIATE;

ADULT; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DIZZINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SKIN REDNESS;

ADRENERGIC ALPHA-AGONISTS; ADULT; ANALYSIS OF VARIANCE; CLONIDINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PSYCHOTHERAPY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT REFUSAL;

EID: 34548686817     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31814e5e9d     Document Type: Article

References (64)

1. O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA. 2005;295:961-963.
2. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2006;1:CD00133.
3. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998;279:229-234.
4. Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev. 2002;1:CD002021.
5. Cornish JW, Metzger D, Woody GE, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat. 1997;14:529-534.
6. Roth A, Hogan L, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat. 1997;14:19-22.
7. Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone for heroin dependence treatment in St Petersburg, Russia. J Subst Abuse Treat. 2004;26:285-294.
8. Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ. 2003;326:959-960.
9. Digiusto E, Shakeshaft A, Ritter A, et al, The NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2005;99:450-460.
10. Fram DH, Marmo J, Holden R. Naltrexone treatment - the problem of patient acceptance. J Subst Abuse Treat. 1989;6:119-122.
11. Forman RF, Bovasso G, Woody G. Staff beliefs about addiction treatment. J Subst Abuse Treat. 2001;21:1-9.
12. Mark TL, Dilonardo JD, Chalk M, et al. Factors associated with the receipt of treatment following detoxification. J Subst Abuse Treat. 2003;24:299-304.
13. Carrol KM, Ball SA, Nich D, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58:755-761.
14. Rothenberg JL, Sullivan MA, Church SH, et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23:351-360.
15. Gowing L, Ali R, White J. Opioid antagonists and adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2000;2:CD002021.
16. Amato L, Davoli M, Minozzi S, et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2005;20:CD003409.
17. Hollister LE, Johnson K, Boukhabza D, et al. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend. 1981;8:37-41.
18. Crowley TJ, Wagner JE, Zerbe G, et al. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry. 1985;142:1081-1084.
19. King AC, Volpicelli JR, Gunduz M, et al. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res. 1997;21:906-909.
20. Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology. 2001;154:397-402.
21. Lee MC, Wagner HN Jr, Tanada S, et al. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1988;29:1207-12011.
22. Bradley BP, Phillips G, Green L, et al. Circumstances surrounding the initial lapse to opiate use following detoxification. Br J Psychiatry. 1989;154:354-359.
23. De Vries TJ, Schoffelmeer AN, Binnekade R, et al. Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. Eur J Neurosci. 1998;11:3565-3571.
24. Koob GF, Ahmed SH, Boutrel B, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2004;8:739-749.
25. Shen KF, Crain SM. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 1997;757:176-190.
26. Powell KJ, Abul-Husn NS, Jhamandas A, et al. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther. 2002;2:588-596.
27. Mannelli P, Gottheil E, Peoples JF, et al. Chronic very low dose naltrexone administration attenuates opioid withdrawal expression. Biol Psychiatry. 2004;56:261-268.
28. Lorenzi P, Marsili M, Boncinelli S, et al. Searching for a general anaesthesia protocol for rapid detoxification from opioids. Eur J Anaesthesiol. 1999;16:719-727.
29. Mannelli P, Gottheil E, Buonanno A, et al. Use of very-low dose naltrexone during opiate detoxification. J Addict Dis. 2003;22:63-70.
30. Chindalore VL, Cravven RA, Yu KP, et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005;6:392-399.
31. Judson BA, Carney TM, Goldstein A. Naltrexone treatment of heroin addiction: efficacy and safety in a double-blind dosage comparison. Drug Alcohol Depend. 1981;7:325-346.
32. Shufman EN, Porat S, Witztum E, et al. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry. 1994;35:935-945.
33. Rabinowitz J, Cohen H, Tarrasch R, et al. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend. 1997;25:77-86.
34. Rea F, Bell JR, Young MR, et al. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend. 2004;75:79-88.
35. Comer SD, Collins ED, Kleber HD, et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology. 2002;159:351-360.
36. Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totaling 101 patients with a note on naltrexone blood levels. Addict Biol. 2003;8:211-217.
37. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210-218.
38. Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30:480-490.
39. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002207.
40. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database Syst Rev. 2005;2:CD004580.
41. Fiorentine R, Anglin MD. Does increasing the opportunity for counseling increase the effectiveness of outpatient drug treatment? Am J Drug Alcohol Abuse. 1997;23:369-382.
42. O'Toole TP, Strain EC, Wand G, et al. Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. J Gen Intern Med. 2002;17:334-340.
43. Etheridge RM, Hubbard RL, Anderson J, et al. Treatment structure and program services in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav. 1997;11:244-260.
44. Fagan RW, Mauss AL. Padding the revolving door: an initial assessment of the Uniform Alcoholism and Intoxication Treatment Act in practice. Soc Probl. 1978;26:232-247.
45. Chutuape MA, Jasinski DR, Fingerhood MI, et al. One, three, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse. 2001;27:19-44.
46. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: The Guilford Press; 1981.
47. Marlatt GA, Gordon JR. Relapse Prevention. New York: The Guilford Press; 1985.
48. Johnson PL. Evaluation of US Public Health Service programs. Organization and management. Eval Health Prof. 1996;19:311-324.
49. Derogatis LR, Yevzeroff H, Wittelsberger B. Social class, psychological disorder, and the nature of the psychopathologic indicator. J Consult Clin Psychol. 1975;43:183-191.
50. Beck AT. Beck Depression Inventory Manual. New York: Harcourt, Brace, Jovanovich, Inc; 1987.
51. Najavits LM, Gastfriend DR, Nakayama EY, et al. A measure of readiness for substance abuse treatment: psychometric properties of the RAATE-R interview. Am J Addict. 1997;6:74-82.
52. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
53. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
54. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;4:491-503.
55. Greenstein RA, O'Brien CP, McLellan AT, et al. Naltrexone: a short-term treatment for opiate dependence. Am J Drug Alcohol Abuse. 1981;8:291-300.
56. Tennant FS Jr, Rawson RA, Cohen AJ, et al. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry. 1984;45:42-45.
57. Ling W, Wesson DR, Charuvastra C, et al. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401-407.
58. Johnson RE, Chatuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290-1297.
59. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038-1041.
60. O'Malley SS, Krishnan-Sarin S, Farren C, et al. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology. 2002;160:19-29.
61. King M, Nazareth I, Lampe F, et al. Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA. 2005;293:1089-1099.
62. Gossop M, Johns A, Green L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. Br Med J. 1986;293:103-104.
63. McKay JR, Rutherford MJ, Alterman AI, et al. An examination of the cocaine relapse process. Drug Alcohol Depend. 1995;38:35-43.
64. McKay JR, Alterman AI, McLellan AT, et al. Random versus nonrandom assignment in the evaluation of treatment for cocaine abusers. J Consult Clin Psychol. 1998;66:697-701.